Nova Eye Medical Limited (ASX:EYE)
Australia · Delayed Price · Currency is AUD 0.1170
-0.0030 (-2.50%)
Jun 5, 2026, 3:58 PM AEST
Nova Eye Medical Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Nova Eye Medical stock has a consensus rating of "Buy" and an average price target of $0.38. The average 1-year stock price forecast is 224.79% higher than the current stock price, while the lowest is $0.28 (+139.32%) and the highest is $0.50 (+327.35%).
Price Target: $0.38 (+224.79%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Nova Eye Medical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Financial Forecast
Revenue This Year
32.95M
from 29.27M
Increased by 12.58%
Revenue Next Year
44.40M
from 32.95M
Increased by 34.75%
EPS This Year
-0.02
from -0.04
EPS Next Year
0.00
from -0.02
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is AUD.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 33.5M | ||
| Avg | 33.0M | ||
| Low | 32.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 14.5% | ||
| Avg | 12.6% | ||
| Low | 10.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | -0.02 | ||
| Low | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |